JP2021120379A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021120379A5 JP2021120379A5 JP2021072166A JP2021072166A JP2021120379A5 JP 2021120379 A5 JP2021120379 A5 JP 2021120379A5 JP 2021072166 A JP2021072166 A JP 2021072166A JP 2021072166 A JP2021072166 A JP 2021072166A JP 2021120379 A5 JP2021120379 A5 JP 2021120379A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- formula
- compound
- insomnia
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 18
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 15
- 206010022437 insomnia Diseases 0.000 claims 10
- 208000007848 Alcoholism Diseases 0.000 claims 6
- 208000025746 alcohol use disease Diseases 0.000 claims 6
- 239000002552 dosage form Substances 0.000 claims 4
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 230000005976 liver dysfunction Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 208000020685 sleep-wake disease Diseases 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims 1
- 229960004047 acamprosate Drugs 0.000 claims 1
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 claims 1
- 239000007894 caplet Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229960002563 disulfiram Drugs 0.000 claims 1
- 229960002464 fluoxetine Drugs 0.000 claims 1
- 229960002870 gabapentin Drugs 0.000 claims 1
- 239000007897 gelcap Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- -1 nalmephenem Chemical compound 0.000 claims 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims 1
- 229960004127 naloxone Drugs 0.000 claims 1
- 229960003086 naltrexone Drugs 0.000 claims 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 239000006191 orally-disintegrating tablet Substances 0.000 claims 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims 1
- 229960004431 quetiapine Drugs 0.000 claims 1
- 229960004394 topiramate Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662366960P | 2016-07-26 | 2016-07-26 | |
| US62/366,960 | 2016-07-26 | ||
| US201762536097P | 2017-07-24 | 2017-07-24 | |
| US62/536,097 | 2017-07-24 | ||
| JP2019503994A JP7198197B2 (ja) | 2016-07-26 | 2017-07-25 | 睡眠障害の治療及び予防 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019503994A Division JP7198197B2 (ja) | 2016-07-26 | 2017-07-25 | 睡眠障害の治療及び予防 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021120379A JP2021120379A (ja) | 2021-08-19 |
| JP2021120379A5 true JP2021120379A5 (enExample) | 2021-12-02 |
| JP7291172B2 JP7291172B2 (ja) | 2023-06-14 |
Family
ID=59714072
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019503994A Active JP7198197B2 (ja) | 2016-07-26 | 2017-07-25 | 睡眠障害の治療及び予防 |
| JP2021072166A Active JP7291172B2 (ja) | 2016-07-26 | 2021-04-21 | 睡眠障害の治療及び予防 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019503994A Active JP7198197B2 (ja) | 2016-07-26 | 2017-07-25 | 睡眠障害の治療及び予防 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US10974081B2 (enExample) |
| EP (1) | EP3490563A1 (enExample) |
| JP (2) | JP7198197B2 (enExample) |
| KR (2) | KR102531366B1 (enExample) |
| CN (1) | CN109689058B (enExample) |
| AU (2) | AU2017304898B2 (enExample) |
| BR (1) | BR112019001457A2 (enExample) |
| CA (1) | CA3031388C (enExample) |
| CL (1) | CL2019000190A1 (enExample) |
| EC (1) | ECSP19014247A (enExample) |
| IL (1) | IL264294B (enExample) |
| JO (1) | JOP20190008A1 (enExample) |
| MX (1) | MX388469B (enExample) |
| NZ (1) | NZ750817A (enExample) |
| PH (1) | PH12019500177A1 (enExample) |
| SG (1) | SG11201900486WA (enExample) |
| TN (1) | TN2019000019A1 (enExample) |
| TW (1) | TWI661827B (enExample) |
| WO (1) | WO2018020418A1 (enExample) |
| ZA (1) | ZA201901055B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190008A1 (ar) | 2016-07-26 | 2019-01-24 | Purdue Pharma Lp | علاج ومنع اضطرابات النوم |
| CN111601591A (zh) * | 2018-01-24 | 2020-08-28 | 普渡制药公司 | 睡眠障碍的治疗和预防 |
| CA3097445A1 (en) * | 2018-04-16 | 2019-10-24 | Technologies Hop-Child, Inc. | Systems and methods for the determination of arousal states, calibrated communication signals and monitoring arousal states |
| KR102198846B1 (ko) * | 2018-06-29 | 2021-01-05 | 다인기술 주식회사 | 배뇨에 관한 설문을 수행하는 방법, 시스템 및 비일시성의 컴퓨터 판독 가능 기록 매체 |
| CN111359074B (zh) * | 2018-12-26 | 2022-08-02 | 财团法人工业技术研究院 | 个人化参数学习方法、睡眠辅助装置及存储介质 |
| US11547350B2 (en) | 2018-12-26 | 2023-01-10 | Industrial Technology Research Institute | Personalized parameter learning method, sleep-aid device and non-transitory computer readable medium |
| US12371427B2 (en) * | 2019-01-31 | 2025-07-29 | Purdue Pharma L.P. | Polymorphic forms of a substituted-quinoxaline-type bridged-piperidine compound |
| KR20220062361A (ko) * | 2019-09-13 | 2022-05-16 | 다케다 야쿠힌 고교 가부시키가이샤 | 과도한 졸림의 치료를 위한 오렉신 2 수용체 효능제의 용도 |
| CN114159568B (zh) * | 2020-09-11 | 2025-08-01 | 北京原基华毅生物科技有限公司 | Sik抑制剂在制备用于预防和/或治疗睡眠障碍的药物中的应用 |
| BR112023023702A2 (pt) | 2021-05-21 | 2024-01-30 | Purdue Pharma Lp | Métodos de tratamento da cistite intersticial/síndrome da dor na bexiga |
| TWI804037B (zh) * | 2021-11-02 | 2023-06-01 | 長庚醫療財團法人高雄長庚紀念醫院 | 生酮飲食之評估系統及其運作方法 |
| CN119421705A (zh) * | 2022-06-24 | 2025-02-11 | 普渡制药公司 | 治疗或预防膀胱过度活动综合征的方法 |
| AU2024364388A1 (en) | 2023-10-19 | 2026-03-19 | Purdue Pharma L.P. | Sunobinop for use in method of treating alcohol use disorder |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| ATE301457T1 (de) | 1995-06-12 | 2005-08-15 | Searle & Co | Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor |
| US6572891B1 (en) | 1999-10-23 | 2003-06-03 | Alkaloid Ad | Sublingual oral dosage form |
| DK1491212T3 (da) | 2002-03-29 | 2012-10-29 | Mitsubishi Tanabe Pharma Corp | Middel til behandling af søvnforstyrrelser |
| AU2004238321B2 (en) | 2003-05-07 | 2009-08-27 | Samyang Biopharmaceuticals Corporation | Highly plastic granules for making fast melting tablets |
| US8067603B2 (en) | 2003-09-25 | 2011-11-29 | Solvay Pharmaceuticals B.V. | Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors |
| US7355045B2 (en) | 2004-01-05 | 2008-04-08 | Applera Corporation | Isotopically enriched N-substituted piperazine acetic acids and methods for the preparation thereof |
| WO2006025267A1 (ja) | 2004-08-31 | 2006-03-09 | Mitsubishi Pharma Corporation | Per2タンパク質レベルの低下を作用機序とする睡眠障害治療薬 |
| PL2063861T3 (pl) | 2006-09-15 | 2015-07-31 | Echo Pharmaceuticals Bv | Jednostka dawkowania do podawania podjęzykowego, podpoliczkowego lub doustnego nierozpuszczalnych w wodzie substancji aktywnych farmaceutycznie |
| JP5554709B2 (ja) * | 2007-08-31 | 2014-07-23 | パーデュー、ファーマ、リミテッド、パートナーシップ | 置換キノキサリンタイプピペリジン化合物とその使用 |
| MY173730A (en) | 2008-03-11 | 2020-02-18 | Takeda Pharmaceuticals Co | Orally-disintegrating solid preparation |
| ES2393849T7 (es) * | 2008-07-21 | 2015-01-28 | Purdue Pharma Lp | Compuestos de piperidina puenteada, de tipo quinoxalina sustituida, y usos de los mismos |
| US9290488B2 (en) | 2011-12-01 | 2016-03-22 | Purdue Pharma L.P. | Azetidine-substituted quinoxalines as opioid receptor like-1 modulators |
| US10118927B2 (en) * | 2012-12-27 | 2018-11-06 | Purdue Pharma L.P. | Substituted piperidin-4-amino-type compounds and uses thereof |
| WO2014102592A2 (en) * | 2012-12-27 | 2014-07-03 | Purdue Pharma L.P. | Oxime/substituted quinoxaline-type piperidine compounds and uses thereof |
| JOP20190008A1 (ar) | 2016-07-26 | 2019-01-24 | Purdue Pharma Lp | علاج ومنع اضطرابات النوم |
-
2017
- 2017-06-16 JO JOP/2019/0008A patent/JOP20190008A1/ar unknown
- 2017-07-25 US US16/318,686 patent/US10974081B2/en active Active
- 2017-07-25 JP JP2019503994A patent/JP7198197B2/ja active Active
- 2017-07-25 BR BR112019001457-8A patent/BR112019001457A2/pt not_active Application Discontinuation
- 2017-07-25 KR KR1020217002556A patent/KR102531366B1/ko active Active
- 2017-07-25 MX MX2019001036A patent/MX388469B/es unknown
- 2017-07-25 KR KR1020197004527A patent/KR102210209B1/ko active Active
- 2017-07-25 TW TW106124940A patent/TWI661827B/zh active
- 2017-07-25 TN TNP/2019/000019A patent/TN2019000019A1/en unknown
- 2017-07-25 WO PCT/IB2017/054506 patent/WO2018020418A1/en not_active Ceased
- 2017-07-25 SG SG11201900486WA patent/SG11201900486WA/en unknown
- 2017-07-25 CN CN201780046414.XA patent/CN109689058B/zh active Active
- 2017-07-25 EP EP17758282.2A patent/EP3490563A1/en active Pending
- 2017-07-25 NZ NZ750817A patent/NZ750817A/en unknown
- 2017-07-25 CA CA3031388A patent/CA3031388C/en active Active
- 2017-07-25 AU AU2017304898A patent/AU2017304898B2/en active Active
-
2019
- 2019-01-17 IL IL264294A patent/IL264294B/en unknown
- 2019-01-25 CL CL2019000190A patent/CL2019000190A1/es unknown
- 2019-01-25 PH PH12019500177A patent/PH12019500177A1/en unknown
- 2019-02-19 ZA ZA2019/01055A patent/ZA201901055B/en unknown
- 2019-02-26 EC ECSENADI201914247A patent/ECSP19014247A/es unknown
-
2020
- 2020-11-19 AU AU2020273332A patent/AU2020273332B2/en active Active
-
2021
- 2021-03-08 US US17/195,434 patent/US11738023B2/en active Active
- 2021-04-21 JP JP2021072166A patent/JP7291172B2/ja active Active
-
2023
- 2023-06-28 US US18/343,182 patent/US12370191B2/en active Active
-
2025
- 2025-06-16 US US19/239,541 patent/US20260007660A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021120379A5 (enExample) | ||
| JP2010535805A5 (enExample) | ||
| Gancher et al. | Absorption of apomorphine by various routes in parkinsonism | |
| TWI455723B (zh) | 納曲酮及安非他酮於治療超重或肥胖病患之用途 | |
| RU2007140348A (ru) | Способы и композиции для лечения заболеваний цнс | |
| JP2005515966A5 (enExample) | ||
| ES2916649T1 (es) | Composiciones y usos para el tratamiento de la esclerosis múltiple | |
| JP2006506378A5 (enExample) | ||
| RU2010133489A (ru) | Применение ингибиторов гамма-секретазы для лечения рака | |
| JP2010521417A5 (enExample) | ||
| RU2006101225A (ru) | Пероральные лекарственные формы мемантина | |
| JP2016507500A5 (enExample) | ||
| RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
| RU2010109359A (ru) | Азитромицин для лечения кожных заболеваний | |
| WO2025042974A1 (en) | Topical administration of glp-1 receptor agonists | |
| IL275875B2 (en) | Sleep disorder treatment and prevention | |
| JP2704721B2 (ja) | イブプロフエン製剤 | |
| JP2016505050A5 (enExample) | ||
| JP2002544227A5 (enExample) | ||
| JPH10505087A (ja) | 非麻薬性鎮痛剤および無痛エンハンサーを含有する疼痛緩和組成物 | |
| IL272834B1 (en) | Compositions of amantadine, their preparation, and methods of use | |
| JP2020533402A5 (enExample) | ||
| JP2008534523A5 (enExample) | ||
| JP2017508737A5 (enExample) | ||
| RU2007139886A (ru) | Композиции для пероральной доставки метформина через слизистые оболочки |